Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
CA 2409910 A1 · Owner: Berner, Bret · Inventors: Louie-Helm, Jenny; Berner, Bret
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Erodible, gastric-retentive dosage forms are provided that are formulated using the in, vitro drug release profile obtained with USP Disintegration test equipment rather the USP, Dissolution Apparatus. The invention is premised on the discovery that the USP Disintegration, Test and modified versions thereof are far more predictive of the in viva release profile for a, controlled release dosage form than is the standard USP Dissolution Test particularly controlled, release dosage forms of the swellable. erodible type. The dosage forms generally comprise, particles of a biocompatible hydrophilic polymer having the active agent incorporated therein, wherein the particles are optionally …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 25, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 25, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 25, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.